Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 16/20 | 0.57 |
| ▸ | ITGA1 | P56199 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | F10 | P00742 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7336000 | 0.86 | F2 (0.50) | F2ITGA1MEN1KMT2AESR1 | |
| SCHEMBL6750357 | 0.83 | F2 (0.59) | F2MEN1KMT2AESR1ATM | |
| SCHEMBL6745851 | 0.83 | F2 (0.56) | F2MEN1KMT2AESR1ATM | |
| SCHEMBL7336404 | 0.81 | TDP1 (0.60) | F2ITGA1MEN1KMT2ATDP1 | |
| SCHEMBL6747382 | 0.79 | F2 (0.60) | F2MEN1KMT2AESR1ATM | |
| SCHEMBL5676119 | 0.75 | F2 (0.60) | F2MEN1KMT2AESR1ATM | |
| SCHEMBL7440192 | 0.75 | F2 (0.55) | F2MEN1KMT2AF10CYP3A4 | |
| SCHEMBL7437719 | 0.71 | F2 (0.56) | F2F10 | |
| SCHEMBL7445021 | 0.70 | F2 (0.56) | F2ITGA1F10CYP1A2CYP2C19 | |
| SCHEMBL5674206 | 0.70 | F2 (0.60) | F2MEN1KMT2AESR1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6635637-B2 | Cyclic oxyguanidine derivatives useful as enzyme inhibitors, and particularly to a new class of non- peptidic inhibitors of proteolytic enzymes; treats pancreatitis, thrombosis, ischemia, stroke, restenosis, emphysema and inflammation | DIMENSIONAL PHARMACEUTICALS, INC. | 2003-10-21 | — | — | US | disclosed |
| EP-1307432-A1 | CYCLIC OXYGUANIDINE PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2003-05-07 | — | — | EP | disclosed |
| US-20020022615-A1 | Cyclic oxyguanidine protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-02-21 | — | — | US | disclosed |
| WO-2002012207-A1 | CYCLIC OXYGUANIDINE PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020022615-A1 | Cyclic oxyguanidine protease inhibitors | PLG, TFPI, PLAT | F2 11/4885ITGA1 751/4885MEN1 4790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.